Phaseline

Companies › Orchard Therapeutics

Orchard Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OTL-203
Autologous CD34+ enriched hematopoietic stem and progenitor cells transduced with lentivir
–Phase 3MPS-IH (Hurler Syndrome)Mar 2028
Atidarsagene Autotemcel (OTL-200)
ARSA exogenous gene
ARSAPhase 3Lysosomal Storage DiseasesMar 2031
Autologous CD34+ hematopoietic stem and progenitor cells genetically modified wi
Lentiviral vector-mediated gene therapy delivering human α-L-iduronidase (IDUA) cDNA to au
IDUAPhase 1Mucopolysaccharidosis IHJan 2035

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06149403OTL-203Phase 3MPS-IH (Hurler Syndrome)Metabolic and endocrineMar 2028
NCT04283227Atidarsagene Autotemcel (OTL-200)Phase 3Lysosomal Storage DiseasesMetabolic and endocrineMar 2031
NCT03488394Autologous CD34+ hematopoietic stem and progenitor cells genetically modified wiPhase 1Mucopolysaccharidosis IHMetabolic and endocrineJan 2035

Targets

IDUA (1) ARSA (1)

Companies with the same targets

–

Companies built like this

Spur Therapeutics iECURE Yong Zhao, MD, PhD Estar Medical dba Medical Technologies Wellizen Australia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.